Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy – a systemic literature view and network meta-analysis. EClinicalMedicine. 2022;48:101412.

Article  PubMed  PubMed Central  Google Scholar 

• Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative trials. Clin Infect Dis. 2020;71(6):1379–89. A comprehensive analysis comparing weight gain between various antiretrovirals using pooled data from antiretroviral initiation randomized controlled trials.

Article  CAS  PubMed  Google Scholar 

Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484. https://doi.org/10.1002/jia2.25484.

Article  PubMed  PubMed Central  Google Scholar 

Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020;7(10):e677–87.

Article  PubMed  Google Scholar 

Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666–76.

Article  PubMed  Google Scholar 

Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–15.

Article  CAS  PubMed  Google Scholar 

Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, et al. Brief report: weight gain following ART initiation in ART-naïve people living with HIV in the current treatment era. J Acquir Immune Defic Syndr. 2021;86(3):339–43.

Article  PubMed  PubMed Central  Google Scholar 

• Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73(8):1440–51. A comprehensive analysis comparing weight gain between various antiretrovirals using pooled data from antiretroviral regimen switch trials.

Article  CAS  PubMed  Google Scholar 

Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–31.

Article  PubMed  PubMed Central  Google Scholar 

Palella FJ, Hou Q, Li J, Mahnken J, Carlson KJ, Durham M, et al. Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide. J Acquir Immune Defic Syndr. 2023;92(1):67–75.

Article  CAS  PubMed  Google Scholar 

Verburgh ML, Wit FWNM, Boyd A, Verboeket SO, Reiss P, van der Valk M. One in 10 virally suppressed persons with HIV in the Netherlands experiences ≥10% weight gain after switching to tenofovir alafenamide and/or integrase strand transfer inhibitor. Open Forum Infect Dis. 2022;9(7):ofac291.

Article  PubMed  PubMed Central  Google Scholar 

Verboeket SO, Boyd A, Wit FW, Verheij E, Schim van der Loeff MF, Kootstra N, et al. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants. PLoS ONE. 2021;16(5):e0251205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y-W, Anderson D, Pericone CD, Donga P. Real-world assessment of weight change in African American females and Hispanics with HIV-1 after initiating integrase strand-transfer inhibitors or protease inhibitors. J Health Econ Outcomes Res. 2022;9(1):1–10.

Article  PubMed  PubMed Central  Google Scholar 

Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter? Open Forum Infect Dis. 2021;8(12):ofab542.

Article  PubMed  PubMed Central  Google Scholar 

Leonard MA, Cindi Z, Bradford Y, Bourgi K, Koethe J, Turner M, et al. Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens. Clin Infect Dis. 2021;73(7):e2153–63.

Article  CAS  PubMed  Google Scholar 

Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M, et al. CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz. Clin Infect Dis. 2021;73(11):e3902–9.

Article  CAS  PubMed  Google Scholar 

Griesel R, Kawuma AN, Wasmann R, Sokhela S, Akpomiemie G, Venter WDF, et al. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022;88(3):883–93.

Article  CAS  PubMed  Google Scholar 

Huang S-H, Huang W-C, Lin S-W, Chuang Y-C, Sun H-Y, Chang S-Y, et al. Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV. J Acquir Immune Defic Syndr. 2021;87(2):834–41.

Article  CAS  PubMed  Google Scholar 

Poeta J, Linden R, Venzon Atunes M, Real L, Magalhães Menezes A, Riberio JP, et al. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. J Antimicrob Chemother. 2011;66(11):2601–4.

Article  CAS  PubMed  Google Scholar 

Shah S, Pilkington V, Hill A. Is tenofovir disoproxil fumarate associated with weight loss? AIDS. 2021;35(Suppl 2):S189–95.

Article  CAS  PubMed  Google Scholar 

McCann K, Shah S, Hindley L, Hill A, Qavi A, Simmons B, et al. Implications of weight gain with newer antiretrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021;35(10):1657–65.

PubMed  Google Scholar 

Nolan NS, Adamson S, Reeds D, O’Halloran JA. Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus. Open Forum Infect Dis. 2021;8(5):ofab077.

Article  PubMed  PubMed Central  Google Scholar 

O’Halloran JA, Sahrmann J, Parra-Rodriguez L, Vo DT, Butler AM, Olsen MA, et al. Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with human immunodeficiency virus. Clin Infect Dis. 2022;75(12):2060–5.

Article  PubMed  Google Scholar 

Summers NA, Lahiri CD, Angert CD, Aldredge A, Mehta CC, Ofotokun I, et al. Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women. J Acquir Immune Defic Syndr. 2020;85(3):355–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, Moore RD, et al. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. Clin Infect Dis. 2021;73(7):e2234–42.

Article  CAS  PubMed  Google Scholar 

Petoumenos K, Kuwanda L, Ryom L, Mocroft A, Reiss P, De Wit S, et al. Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D:A: D Study. J Acquir Immune Defic Syndr. 2021;86(5):579–86.

Article  CAS  PubMed  Google Scholar 

Neesgaard B, Greenberg L, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV. 2022;9(7):e474–85.

Article  CAS  PubMed  Google Scholar 

Yu MA, Gerig L, Mehta CC, Yusef O, Musonge-Effoe J, Alvarez J, et al. Noninvasive assessment of change in hepatic fibrosis following initiation of integrase inhibitors in women living with HIV. ID Week 2022 Conference, October 19–23, 2022, Washington, DC. Abstract #1276.

McComsey GA, Emond B, Shah A, Bookhart BK, Rossi C, Milbers K, et al. Association between weight gain and the incidence of cardiometabolic conditions among people living with HIV-1 at high risk of weight gain initiated on antiretroviral therapy. Infect Dis Ther. 2022;11(5):1883–99.

Article  PubMed  PubMed Central  Google Scholar 

Wisch JK, Cooley SA, Yarasheski KE, Cade WT, Reeds DN, Nelson B, et al. Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV. Antivir Ther. 2022;27(3):13596535221109748.

Article  CAS  PubMed  Google Scholar 

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. Accessed 20 Feb 2023.

Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63–84.

Article  CAS  PubMed  Google Scholar 

Doravirine for persons with excessive weight gain on integrase inhibitors and tenofovir alafenamide. Available at: https://clinicaltrials.gov/ct2/show/NCT04636437?cond=doravirine+weight&draw=2&rank=2. Accessed 20 Feb 2023.

• Orkin C, Elion R, Thompson M, Rockstroh JK, Alvarez Bognar F, Xu ZJ, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021;35(1):91–9. An analysis of pooled data to assess the effects of doravirine on weight and metabolic profile, as compared to boosted darunavir and to efavirenz.

Article  CAS  PubMed  Google Scholar 

A study of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) evaluated as a fixed dose combination regimen in participants switching from an integrase inhibitor who have experienced rapid weight gain (DEFINE). Available at: https://clinicaltrials.gov/ct2/show/NCT04442737?cond=darunavir+weight&draw=2&rank=1. Accessed 20 Feb 2023.

ClinicalTrials.gov. Available at: https://clinicaltrials.gov/. Accessed 20 Feb 2023.

Dimala CA, Ngu RC, Momo Kadia BM, Tianyi F-L, Choukem SP. Markers of adiposity in HIV/AIDS patients: agreement between waist circumference, waist-to-hip ratio, waist-to-height ratio and body mass index. PLoS ONE. 2018;13(3):e0194653.

Article  PubMed  PubMed Central